Compare Capri Holdings Ltd (CPRI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Twist Bioscience Corp — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while Twist Bioscience Corp trades at $123.13 (market cap $7.82B). The key difference: Twist Bioscience Corp is far larger — about 4.5× Capri Holdings Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | TWST | |
|---|---|---|
Market Cap | $1.75B | $7.82B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $124.88 |
52-Week Low | $14.98 | $24.16 |
Enterprise Value | $3.03B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $15.295, up 2.1% today but near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with moving averages indicating selling pressure, while fundamentals reveal mixed performance - strong gross margins of 62.71% but recent net losses and declining revenue. Recent Q1 2027 earnings beat expectations despite revenue challenges, with the company revising full-year guidance downward due to Michael Kors inventory delays and softer luxury demand.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with Wall Street maintaining a cautious stance (44% buy ratings) despite a $19.60 consensus target representing 28% upside. Key risks include ongoing revenue declines, luxury market volatility, and execution challenges in revitalizing the Michael Kors brand amid competitive pressures.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
